Literature DB >> 18300078

Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.

Matthias Mehling1, Henning Drechsler, Jens Kuhle, Martin Hardmeier, Ruediger Doerries, Stephan Ruegg, Achim Gass.   

Abstract

The authors describe a patient with known human immunodeficiency virus (HIV)-1 infection who presented with two generalized seizures and was found to have extensive white matter disease and a left/bilateral temporo-occipital focal slowing on electroencephalography (EEG). There were no magnetic resonance imaging (MRI) or cerebrospinal fluid (CSF) indications for opportunistic infection. Plasma viremia was controlled, whereas viral replication was uncontrolled in CSF. CSF-specific genotype-guided adaptation of the antiretroviral therapy in order to optimize central nervous system (CNS) penetration resulted in clinical improvement and normalization of MRI and EEG. Our case report illustrates the importance of individualized antiretroviral therapy in HIV infected patients with neurological complications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18300078     DOI: 10.1080/13550280701793940

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  21 in total

1.  Changes to AIDS dementia complex in the era of highly active antiretroviral therapy.

Authors:  G J Dore; P K Correll; Y Li; J M Kaldor; D A Cooper; B J Brew
Journal:  AIDS       Date:  1999-07-09       Impact factor: 4.177

Review 2.  Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults.

Authors:  Zelalem Temesgen; Francesca Cainelli; Eric M Poeschla; Stacey A R Vlahakis; Sandro Vento
Journal:  Lancet Infect Dis       Date:  2006-08       Impact factor: 25.071

Review 3.  Central nervous system dysfunction in acquired immunodeficiency syndrome.

Authors:  R M Levy; D E Bredesen
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1988

4.  Depletion of latent HIV-1 infection in vivo: a proof-of-concept study.

Authors:  Ginger Lehrman; Ian B Hogue; Sarah Palmer; Cheryl Jennings; Celsa A Spina; Ann Wiegand; Alan L Landay; Robert W Coombs; Douglas D Richman; John W Mellors; John M Coffin; Ronald J Bosch; David M Margolis
Journal:  Lancet       Date:  2005 Aug 13-19       Impact factor: 79.321

Review 5.  HIV pharmacology: barriers to the eradication of HIV from the CNS.

Authors:  Bryan McGee; Nathalie Smith; Francesca Aweeka
Journal:  HIV Clin Trials       Date:  2006 May-Jun

6.  Prospective study of new-onset seizures in patients with human immunodeficiency virus infection: etiologic and clinical aspects.

Authors:  B Pascual-Sedano; A Iranzo; J Marti-Fàbregas; P Domingo; A Escartin; M Fuster; J L Barrio; M A Sambeat
Journal:  Arch Neurol       Date:  1999-05

7.  Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.

Authors:  Janet D Siliciano; Jun Lai; Marc Callender; Eleanor Pitt; Hao Zhang; Joseph B Margolick; Joel E Gallant; Joseph Cofrancesco; Richard D Moore; Stephen J Gange; Robert F Siliciano
Journal:  J Infect Dis       Date:  2007-01-30       Impact factor: 5.226

Review 8.  Neurological complications of HIV infection.

Authors:  Justin C McArthur; Bruce J Brew; Avi Nath
Journal:  Lancet Neurol       Date:  2005-09       Impact factor: 44.182

9.  Seizures associated with ganciclovir therapy.

Authors:  T L Barton; M K Roush; L L Dever
Journal:  Pharmacotherapy       Date:  1992       Impact factor: 4.705

Review 10.  Anti-HIV drug distribution to the central nervous system.

Authors:  S A Thomas
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

View more
  2 in total

Review 1.  Voltage-gated potassium channels in human immunodeficiency virus type-1 (HIV-1)-associated neurocognitive disorders.

Authors:  James Keblesh; Dehui Hu; Huangui Xiong
Journal:  J Neuroimmune Pharmacol       Date:  2008-05-06       Impact factor: 4.147

Review 2.  Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration?

Authors:  P P Koopmans; R Ellis; B M Best; S Letendre
Journal:  Neth J Med       Date:  2009-06       Impact factor: 1.422

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.